Literature DB >> 12594881

Wound infection after infrainguinal bypass operations: multivariate analysis of putative risk factors.

E S Lee1, S M Santilli, M M Olson, M A Kuskowski, J T Lee.   

Abstract

Reported wound infection rates for infrainguinal bypass operations range from 17% to 44%, but there is limited appreciation of which characteristics of patients or operations are reliable markers of increased wound infection risk. The purpose of the present study was to analyze all wound infections observed after infrainguinal bypass operations during 20 years of practice in a large teaching institution. Independent risk factors for wound infection development were identified. During the 20-year period ending 31 December, 1997, 978 male patients underwent infrainguinal bypass operations at the Minneapolis Department of Veterans Affairs Medical Center. Wound infections complicated the recovery of 129 of these patients during a 30-day postoperative surveillance interval. Multivariate logistic regression analysis was used to test the association between wound infection occurrence and putative risk factors that were either features of patients or characteristics of the operations. The following variables were examined: obesity, prosthetic graft placement, diabetes mellitus, steroid use, anticoagulation use, length of preoperative hospital stay, development of incisional hematoma, duration of operation, and the preoperative presence of a non-healing wound in the extremity being revascularized. The overall wound infection rate was 13.2% (129/978). In a final logistic regression model, obesity was a significant and independent predictor of wound infection (Relative Risk 2.6, 95% confidence interval, 1.35-4.90), as was development of a post-operative incisional hematoma (Relative Risk 6.44, 95% confidence interval, 2.95-14.08). No other explanatory variable was significantly associated with wound infection development.

Entities:  

Mesh:

Year:  2000        PMID: 12594881     DOI: 10.1089/109629600750067183

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  7 in total

1.  Intra-arterial Device Infections.

Authors:  Vera S. Antonios; Larry M. Baddour
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

2.  Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia.

Authors:  Louis L Nguyen; Soma Brahmanandam; Dennis F Bandyk; Michael Belkin; Alexander W Clowes; Gregory L Moneta; Michael S Conte
Journal:  J Vasc Surg       Date:  2007-12       Impact factor: 4.268

3.  Body mass index: surgical site infections and mortality after lower extremity bypass from the National Surgical Quality Improvement Program 2005-2007.

Authors:  Kristina A Giles; Allen D Hamdan; Frank B Pomposelli; Mark C Wyers; Jeffrey J Siracuse; Marc L Schermerhorn
Journal:  Ann Vasc Surg       Date:  2009-07-19       Impact factor: 1.466

Review 4.  Surgical site infections in older adults: epidemiology and management strategies.

Authors:  Michael H Young; Laraine Washer; Preeti N Malani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  Nosocomial infections after peripheral arterial bypass surgery.

Authors:  Arianne Ploeg; Christopher Lange; Jan-Willem Lardenoye; Paul Breslau
Journal:  World J Surg       Date:  2007-08       Impact factor: 3.352

Review 6.  Groin Surgical Site Infection in Vascular Surgery: Systemic Review on Peri-Operative Antibiotic Prophylaxis.

Authors:  Bruno Amato; Rita Compagna; Salvatore De Vivo; Aldo Rocca; Francesca Carbone; Maurizio Gentile; Roberto Cirocchi; Francesco Squizzato; Andrea Spertino; Piero Battocchio
Journal:  Antibiotics (Basel)       Date:  2022-01-20

7.  Negative pressure wound therapy for high-risk wounds in lower extremity revascularization: study protocol for a randomized controlled trial.

Authors:  Patrick Murphy; Kevin Lee; Luc Dubois; Guy DeRose; Thomas Forbes; Adam Power
Journal:  Trials       Date:  2015-11-04       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.